UTMB develops a universal vaccine platform that’s cheaper and shelf stable
Researchers at The University of Texas Medical Branch at Galveston have developed a less expensive way to produce vaccines that cuts the cost of vaccine production and storage by 80 percent without decreasing safety or effectiveness. The findings are currently available in EBioMedicine.
Vaccines are the most effective way to prevent and eradicate infectious diseases. Currently, many vaccines have to be manufactured in cell culture or eggs, which is expensive and carries the risk of contaminations. In addition, most vaccines must be kept refrigerated during the transportation from manufacturers to health care clinics. In tropical and subtropical regions, such cold storage requirements could contribute to more than 80 percent of the vaccine cost.
“The ability to eliminate cell culture or eggs and cold storage will change the process of vaccine development,” said UTMB’s Pei-Yong Shi, professor in the department of biochemistry and molecular biology. “Importantly, this vaccine technology could potentially serve as a universal platform for development of live-attenuated vaccines for many viral pathogens.”
To achieve these goals, the UTMB team engineered a live-attenuated Zika vaccine in the DNA form. Once the DNA is delivered into our body, it launches the vaccine in our cells, leading to antibody production and other protective immunity. With this production method, there is no need to manufacture the vaccine in cell culture or eggs at factories. Because DNA molecules are shelf stable, the vaccine will not expire at warm temperatures and could be stockpiled at room temperature for years.
Using UTMB’s Zika vaccine as a model, the research group showed that the DNA platform worked very efficiently in mice. After a single low dose, the DNA vaccine protected mice from Zika virus infection, mother-to-fetus transmission during pregnancy and male reproductive tract infection and damage.
“This is the first study to demonstrate that, after a single low dose, a DNA vaccine could induce saturated protective immunity,” Shi said. “We will continue testing this promising Zika vaccine platform and then apply the platform to other viruses.”
The Latest on: Vaccine production
via Google News
The Latest on: Vaccine production
- Why CRISPR may work when vaccines don't on February 20, 2019 at 12:57 pm
Researchers are using the gene-editing tool CRISPR to skip a step in antibody production in hopes of turning patients' immune systems against viruses that have no vaccines, STAT reports. Vaccines work ... […]
- Global Recombinant Vaccines Market : By key players, product and production information analysis and forecast to 2028 on February 20, 2019 at 10:41 am
The report gives the research-based overview of on Global Recombinant Vaccines Market 2019 size, industry status and forecast, competition landscape and growth opportunity. This research report catego... […]
- Oral vaccine developed by MSU improves production and profitability of catfish producers on February 20, 2019 at 7:20 am
Vaccination technologies developed in Mississippi State are being commercialized to help the catfish industry save millions by minimizing losses from enteric septicemia (ESC), a common bacterial disea... […]
- Oral vaccine could save US catfish farmers millions on February 20, 2019 at 2:38 am
“The application technology is revolutionary. It may be a gateway for the development of other vaccines because it provides a practical and effective mechanism to orally apply vaccines in food fish pr... […]
- Vaccines don’t work against some viruses. CRISPR might one day fix that on February 19, 2019 at 1:49 am
There are many reasons why, including how hard it is to identify the exact piece of an antigen that will trigger production of an effective antibody. And even when vaccines exist, they fail when B cel... […]
- Peptide Cancer Vaccine Market on February 18, 2019 at 10:11 am
production, market share analysis, sales overview, supply, sales, and shortage, import, export and consumption as well as cost, price, revenue and gross margin of Peptide Cancer Vaccine Market. 5 Glob... […]
- Are sweet vaccines the future for pigs and poultry? on February 18, 2019 at 9:14 am
which allows us to generate the vaccine directly in a vaccine strain, thus reducing the production cost and making it feasible for the veterinary market. How are your products an innovation on technol... […]
- Newcastle Disease Vaccine market forecast to 2025 published by leading research firm on February 17, 2019 at 11:00 pm
Market Overview: It begins with scope of products offered in the global Newcastle Disease Vaccine market and ends with a chapter on global market size by production and revenue. Market Competition: He... […]
- At 7.6% CAGR, Anthrax Vaccines Market Size Projected to cross USD 840 Million by 2025 on February 17, 2019 at 10:41 pm
South America region is the largest supplier of Anthrax Vaccines, with a production market share nearly 34.7% in 2016. Europe is the second largest supplier of Anthrax Vaccines, enjoying production ma... […]
via Bing News